Last reviewed · How we verify
NCT06590961
A Phase Ia/Ib, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic of UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
Phase 1 trial testing UBX-303061 in Relapsed/Refractory B-cell Malignancies in 94 participants. Currently enrolling.
1 August 2027
Quick facts
| Lead sponsor | Ubix Therapeutics, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 94 |
| Start date | 20 February 2025 |
| Primary completion | 1 August 2027 |
| Estimated completion | 1 August 2027 |
| Sites | 11 locations across United States, Poland, South Korea |
Drugs / interventions tested
- UBX-303061 — full drug profile →
Conditions studied
- Relapsed/Refractory B-cell Malignancies — all drugs for Relapsed/Refractory B-cell Malignancies →
Sponsor
Ubix Therapeutics, Inc. — full company profile →
Who can join
18 and older, any sex, with Relapsed/Refractory B-cell Malignancies. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Number of subjects with Protocol Specified Dose-Limiting Toxicities
Time frame: 28-days
Phase 1a and 1b -
To establish the maximum tolerated dose and/or recommended Phase 1b dose(s)
Time frame: Up to End of Treatment (up to 9 months)
Phase 1a and 1b -
Number of subjects with dose interruptions, reductions, and doses administered
Time frame: Up to End of Treatment (up to 9 months)
Phase 1a and qb
Sponsor's own description
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications.
Knoll N, Neamati N, Üren A. · · 2026 · PMID 41988372 · DOI 10.1021/acsptsci.5c00730
Verify or expand the search:
- PubMed search for NCT06590961
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Relapsed/Refractory B-cell Malignancies
Currently open trials in the same condition.
- NCT07345728 — Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies · NA · recruiting
- NCT07309900 — IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies · Phase 1 · recruiting
- NCT07240974 — Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies · EARLY_PHASE1 · recruiting
- NCT07002112 — The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies · Phase 1 · recruiting
- NCT05780034 — A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06590961 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ubix Therapeutics, Inc.
- Last refreshed: 16 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06590961.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing